Edaravone mitigates cognitive impairment and hippocampal injury in juvenile rats with obstructive sleep apnea hypopnea syndrome via regulation of cAMP/PKA-CREB pathway

Yongmei Zhao¹, Hongli Li², Yong Chen¹, Kexing Li², Sufei Yang³*
¹Department of Paediatrics, ²Department of Neonatology, Longquanyi District of Chengdu Maternity & Child Health Care Hospital, Chengdu 610100, ³Department of Child Health Care, West China Second Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
*For correspondence: Email: fpudr3@163.com

Sent for review: 30 June 2021 Revised accepted: 22 October 2021

Abstract

Purpose: To investigate the influence of edaravone on cognitive impairment and hippocampal injury in juvenile rats with obstructive sleep apnea hypopnea syndrome (OSAHS), and the mechanism involved.

Methods: Fifty-four young Wistar rats were randomly selected into control, intermittent hypoxia and edaravone groups. The contents of the antioxidants CAT, Mn-SOD, Cu/Zn SOD and oxidative stress products malondialdehyde (MDA) in hippocampus were assayed and compared. The expressions of brain-derived neurotrophic factor (BDNF), Bcl-2, CREB, p-CREB and PKAc were determined.

Results: The times taken to cross the target quadrant and the platform; levels of CAT and Mn-SOD, as well as protein levels of BDNF, Bcl-2, p-CREB and PKAc were markedly lower in intermittent hypoxia group than in controls; and MDA contents, 8-OHdG and protein hydroxyl were markedly higher in intermittent hypoxic rats group than in controls. Time taken to cross the platform and quadrant; activities of CAT and Mn-SOD, and protein concentrations of BDNF, Bcl-2, p-CREB and PKAc were markedly higher in the edaravone-treated rats than in intermittent hypoxia rats.

Conclusion: Edaravone significantly mitigated cognitive damage and hippocampal lesions in OSAHS rats via a mechanism related to alleviation of oxidative stress and up-regulation of the expressions of p-CREB and its downstream proteins BDNF and Bcl-2. This finding provides a theoretical basis for research and development of new drugs against OSAHS.

Keywords: Obstructive sleep apnea hypopnea syndrome, Edaravone, cAMP, PKA, CREB

INTRODUCTION

In children, OSAHS is characterized by incomplete or total blockage of the upper respiratory tract during sleep. It causes damage to many organs, and leads to memory deterioration, mental retardation, cognitive and behavioral disorders, elevated blood pressure, metabolic disorders and changes in the heart structure [1,2]. A survey has shown that the...
Prevalence of OSAHS in China is about 3.4%. Proadenoidal tonsil hypertrophy in children is the main cause of OSAHS. Therefore, clinical treatment of the disease involves tonsillectomy and adenoidectomy which effectively improve ventilation \[3,4\]. However, factors that induce OSAHS in children are multiple levels of obesity and neuromuscular lesions, leading to the higher incidence of persistent OSAHS which require tonsillectomy and adenoidectomy \[5\]. Therefore, it is important to understand the pathogenesis of OSAHS so as to evolve new treatment methods with improved clinical efficacy.

Edaravone is a free radical-scavenging and antioxidant drug with small molecular weight. At present, it is mainly used in clinical treatment of acute cerebral infarction and other diseases, with ideal clinical efficacy and high degree of safety \[6\]. Clinical studies have confirmed that edaravone relieves impairment in neurobehavior and cognitive function caused by ischemia and hypoxia \[7\]. However, not much has been reported on its effect on OSAHS-induced cognitive impairment. Clinical reports confirm that the OSAHS-induced organ damage is associated with oxidative stress response, while cAMP/protein kinase A (PKA) reaction element binding (CREB) route is associated with cognitive function \[8, 9\]. However, there are limited studies on the involvement of this pathway in OSAHS. This research was aimed at studying the effect of edaravone on OSAHS-induced cognitive impairment and hippocampal injury in juvenile rats, and the role of hippocampal cAMP/PKA-CREB route in the process.

**EXPERIMENTAL**

**Animals**

Fifty-four juvenile Wistar rats aged 3 - 4 weeks were purchased from Zhaoyan New Drug Research Center Co. Ltd [production license no. SCXK (Su) 2020-0015]. All rats were kept in the same environment at a temperature at 25 °C and humidity of 40 %, with free access to feed and water. This study received approval from the Animal Ethics Committee of West China Second Hospital and was conducted in line with "Principles of Laboratory Animal Care" \[10\].

**Main reagents and instruments**

Edaravone was purchased from Beijing Eta Biotechnology Co. Ltd. Paraformaldehyde (4%) was obtained from Lanzhou Weiboxin Biotechnology Co. Ltd. Hematoxylin dyeing solution was bought from Chuzhou Snorda Biological Technology Co. Ltd. BCA protein quantitative kit was product of Shenyang Wanjie Biotechnology Co. Ltd; BDNF and Bcl-2 were purchased from Shanghai Fanwei Biotechnology Co. Ltd, while CREB antibody was obtained from Shanghai Fanwei Biotechnology Co. Ltd. The p-CREB antibody was purchased from Jiangxi Jiang Blue Pure Biological Reagent Co. Ltd, while PKAC antibody was bought from Shanghai Caiyou Industrial Co. Ltd.

Oxygen meter was purchased from Lubo Weiye Environmental Protection Technology Co. Ltd. Low-temperature high speed centrifuge was product of Shanghai Hengfei Biotechnology Co. Ltd. Precision balance was purchased from Nanjing Baden Medical Co. Ltd. Morris Water Maze and its imaging system were bought from Shanghai Sieger Biotechnology Co. Ltd. Optical microscope was purchased from Wuhan Purity Biotechnology Co. Ltd. Automatic embedding machine was product of Hubei Botai Electronic Technology Co. Ltd.

**Treatments**

A total of 18 out of the 54 juvenile Wistar rats were randomly selected as the control group. The rats were placed in a hypoxia chamber from 9:00 a.m. to 5:00 p.m. daily, with intermittent air treatment, but without any drug intervention. The remaining 36 rats were placed in the hypoxia chamber from 9:00 a.m. to 5:00 p.m. every day, for establishment of intermittent hypoxia. The intermittent hypoxia model rats were randomly divided into edaravone group and intermittent hypoxia group, with 18 rats in each group. Rats in the intermittent hypoxia group did not receive any drug intervention. The edaravone group was given edaravone at a dose of 5 mg/kg via intraperitoneal injection before daily exposure to intermittent hypoxia.

**Evaluation of biochemical parameters**

After 5 days of treatment, positioning navigation and space exploration tests were used to determine the time taken to cross the target quadrant, the number of times the rats crossed the platform, as well as their learning and memory abilities were evaluated.

**H & E staining**

The rats were sacrificed under intratracheal instillation anesthesia using the abdominal aorta depletion method. Whole brains were excised and fixed in 10 % neutral formalin for 48 h. Then, the bilateral hippocampal tissues were removed and separated. Pathological changes in neurons...
in CA1 and CA3 hippocampal areas were analyzed using H & E dyes.

**Evaluation of hippocampal tissues**

The contents of catalase (CAT), malondialdehyde (MDA) and protein hydroxyl group in hippocampal tissues of rats were determined using CAT decomposition reaction, thiobarbituric acid method, and Levine's method, respectively. The activities of Mn-SOD and Cu/Zn-SOD, as well as levels of 8-OHDG in hippocampal tissues of rats were determined using ELISA. The hippocampal tissues of rats in each group were subjected to western blot assay for determination of protein expression levels of brain-derived neurotrophic factor (BDNF), Bcl-2, CREB, p-CREB and PKAC. The kits used were purchased from Jianchen Biotech (Nanjing, China).

**Statistical analysis**

Measurement data for activities CAT, Mn-SOD and Cu/Zn-SOD which conformed to normal distribution are presented as mean ± SD. Comparison amongst groups was done using one-way ANOVA. Two-group comparison was done with SNK-Q test. All statistical analyses were done with SPSS version 22.0. Values of $p < 0.05$ indicated significant differences.

**RESULTS**

**Learning and memory abilities**

The times taken to cross the target quadrant and the platform in the intermittent hypoxia group were markedly lower than those in controls ($p < 0.05$). In contrast, the time taken to cross the target quadrant and the platform were markedly higher in edaravone-exposed rats than in intermittent hypoxic rats. These results are presented in Table 1.

**Pathological changes in hippocampal tissues**

In the control group, neurons in hippocampal CA1 and CA3 zones were arranged neatly, the cytoplasm and nucleus were visible, and there were no obvious pathological changes. In the intermittent hypoxia group, the spaces around the neurons in hippocampal CA1 and CA3 regions were increased, and the morphological integrity of the cells was damaged; the nuclei were degenerated, and the nucleoli were unclear. In contrast, the morphology and structure of hippocampal CA1 and CA3 neurons in edaravone group were significantly improved, when compared with the intermittent hypoxia group. These results are shown in Figure 1.

**Table 1:** Learning and memory abilities amongst the groups (mean ± SD, n = 18)

| Group               | Time taken to cross the target quadrant (s) | Time taken to cross the platform (s) |
|---------------------|---------------------------------------------|--------------------------------------|
| Control             | 43.21±5.22                                  | 5.96±1.46                            |
| Intermittent hypoxia| 30.22±7.48 *                                | 3.41±1.23 *                          |
| Edaravone           | 39.90±8.07 #†                               | 5.26±1.60 #†                          |
| $F$                 | 16.590                                      | 15.11                                |

*P < 0.05, vs control; #p < 0.05, vs intermittent hypoxic rats

**Levels of antioxidant enzymes in hippocampal tissues**

The contents of CAT and Mn-SOD in intermittent hypoxic rats were markedly reduced, relative to control. However, CAT and Mn-SOD contents in edaravone-exposed rats were markedly higher than the corresponding levels in intermittent hypoxic rats. There was no significant difference in Cu/Zn-SOD content amongst the groups ($p > 0.05$). These results are shown in Table 2.

**Table 2:** Comparison of CAT, Mn-SOD and Cu/Zn-SOD contents in hippocampus (mean ± SD, n = 18)

| Group               | CAT (U/mg) | Mn-SOD (pg/mL) | Cu/Zn-SOD (pg/mL) |
|---------------------|------------|----------------|-------------------|
| Control             | 24.10±3.11 | 150.93±11.69   | 1441.72±223.43    |
| Intermittent hypoxia| 14.90±2.40 | 119.32±11.05   | 1322.50±233.02    |
| Edaravone           | 21.15±4.28†| 140.61±9.31†   | 1259.78±229.22†   |
| $F$                 | 35.310     | 40.620         | 2.940             |

*P < 0.05, vs control; #p < 0.05, vs intermittent hypoxic rats
Hippocampal levels of oxidative stress products

The levels of MDA, 8-OHdG and protein hydroxyl in hypoxic rats were markedly higher than the control values. However, MDA, 8-OHdG and protein hydroxyl contents in edaravone group were markedly lower than the corresponding levels in intermittent hypoxia groups (p < 0.05; Table 3).

Hippocampal tissue protein levels of PKAC, CREB, p-CREB, BDNF and Bcl-2

There were significantly downregulated protein levels of BDNF, Bcl-2, p-CREB and PKAC in intermittent hypoxic rats, relative to control rats. However, the expressions of BDNF, Bcl-2, p-CREB and PKAC in the edaravone group were markedly up-regulated, relative to the corresponding levels in intermittent hypoxic rats. There was no appreciable difference in CREB protein level between the control and intermittent hypoxia groups. These results are shown in Table 4.

DISCUSSION

It has been reported that edaravone significantly inhibited tissue edema induced by ischemia or embolism in animals [11, 12]. In addition, edaravone significantly mitigated hippocampal oxidative stress-induced damage caused by sleep deprivation, through a mechanism linked to the normalization of oxidative balance [13]. However, there are limited studies on the effect of edaravone on OSAHS at present. Therefore, it is of great significance to investigate the therapeutic effect of edaravone on cognitive dysfunction in children with OSAHS.

Table 3: Comparison of levels of MDA, 8-OHdG and protein hydroxyl groups in hippocampus (mean ± SD)

| Group              | MDA (nmol/mg) | 8-OHdG (ng/mL) | Protein hydroxyl (nmol/mg) |
|--------------------|---------------|----------------|---------------------------|
| Control            | 1.75±0.33     | 0.49±0.07      | 3.62±0.64                 |
| Intermittent hypoxia| 5.26±0.49*    | 0.64±0.09*     | 5.73±0.95*                |
| Edaravone          | 2.04±0.42#    | 0.52±0.06#     | 3.98±0.81#                |
| F                  | 20.490        | 40.720         |                           |

*P < 0.05, vs control; #p < 0.05, vs intermittent hypoxia group

Table 4: Comparison of protein expression levels of BDNF, Bcl-2, CREB, p-CREB and PKAC in hippocampal tissues (mean ± SD)

| Group              | BDNF          | Bcl-2         | p-CREB        | CREB          | PKAc          |
|--------------------|---------------|---------------|---------------|---------------|---------------|
| Control            | 0.78±0.02     | 0.36±0.02     | 0.75±0.03     | 0.86±0.05     | 0.52±0.03     |
| Intermittent hypoxia| 0.63±0.01*    | 0.22±0.01*    | 0.38±0.02*    | 0.87±0.01     | 0.28±0.02*    |
| Edaravone          | 0.79±0.03#    | 0.33±0.03#    | 0.71±0.04#    | 0.85±0.01#    | 0.48±0.04#    |
| F                  | 309.860       | 209.570       | 767.790       | 0.670         | 307.860       |
| P-value            | <0.001        | <0.001        | <0.001        | 0.518         | <0.001        |

*P < 0.05, vs control; #p < 0.05, vs intermittent hypoxia group

The results from this research revealed that the times taken to cross the target quadrant and the platform were markedly shorter in the hypoxia group than the corresponding times in control group. However, the times taken to cross the target quadrant and the platform in the edaravone group were significantly longer than those in intermittent hypoxia group. These results suggest that intermittent hypoxia caused severe damage to hippocampal nerve cells in young rats, but this damage was significantly alleviated with edaravone.

Oxidative stress occurs in OSAHS patients due to chronic intermittent hypoxia and reoxygenation, and it is usually manifested as an raised superoxide content and reduced antioxidant enzyme content. These lead to a decrease in total antioxidant capacity in the body, resulting in damage to tissues and organs [14,15]. In this study, SOD and antioxidant enzyme-related indices were used to evaluate the degree of oxidative stress in rats in each group. The results showed that the contents of CAT and Mn-SOD were markedly reduced in the intermittent hypoxic rats, relative to the control group, while MDA, 8-OHdG and protein hydroxyl groups were significantly higher.

However, CAT and Mn-SOD contents were markedly higher in edaravone group than in intermittent hypoxia group. This indicates that intermittent hypoxia provoked oxidation-linked stress response in the animals, but edaravone neutralized the ROS and oxidative imbalance,
thereby mitigating hippocampal injury. It has been reported that hypoxia induced decreases in p-CREB expression, leading to a significant decrease in learning and memory ability of animals in water maze and avoidance tests [16]. However, treatment with N-methyl-D-aspartic acid receptor antagonist significantly increased the expression level of p-CREB [16].

Activation of cAMP/PKA pathway led to increased mitochondrial activity, thereby reducing the release of ROS, indicating that edaravone not only eliminated ROS through single electron transfer, but also increased the ROS clearance intensity through activation of this pathway [17-20]. It is known that BDNF is a downstream molecule of phosphorylated CREB gene transcription, and its levels are highest in CNS, hippocampus and cortex. Moreover, BDNF regulates the protrusion plasticity of hippocampal neurons and mediates long-term enhancement of related links in the hippocampus. Dead weight leads to changes in learning and memory ability. Another downstream molecule of CREB-mediated gene transduction is Bcl-2 which is an anti-apoptotic factor. It has been reported that overexpression of Bcl-2 significantly reduced the release of oxygen-free radicals and generation of lipid peroxides through suppression of the release of superoxide anions.

The results of this study showed that the protein expression levels of BDNF, Bcl-2, p-CREB and PKAC in the intermittent hypoxia group were markedly smaller than control values, but they were markedly up-regulated in edaravone group, relative to intermittent hypoxia group. These results suggest that the cAMP/PKA-CREB pathway may be involved in the development of cognitive dysfunction caused by intermittent hypoxia, and edaravone may play a mitigating role in cognitive impairment and hippocampal injury in young mice by regulating this pathway.

CONCLUSION

Edaravone significantly alleviates cognitive dysfunction and hippocampal injury in OSAHS rats via mechanisms involving mitigation of oxidative stress response and up-regulation of p-CREB and its downstream molecules, BDNF and Bcl-2. This finding provides a theoretical basis for research and development of new drugs against OSAHS.

DECLARATIONS

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

1. Zhang T, Zhang C, Chen RX, Shao B, Liu GA. Correlation between coronary artery lesion quantitative score and OSAHS and relative risk factors. Eur Rev Med Pharmacol Sci 2018; 22(5): 1415-1420.
2. Zhang H, Yang F, Guo Y, Wang L, Fang F, Wu H, Nie S, Wang Y, Fung ML, Huang Y, Deng H, Qin Y, Ma X, Wei Y. The contribution of chronic intermittent hypoxia to OSAHS: From the perspective of serum extracellular microvesicle proteins. Metabolism 2018; 85: 97-108.
3. Coutinho Costa J, Rebelo-Marques A, Machado JN, Gama JMR, Santos C, Teixeira F, Moita J. Validation of NoSAS (Neck, Obesity, Snoring, Age, Sex) score as a screening tool for obstructive sleep apnea: Analysis in a sleep clinic. Pulmonology 2019; 25(5): 263-270.
4. Navarro-Antolin J, Carmona-Bernal C, Rivero-Valdenebro V, Villar J, Capote F, Lopez-Barneo J. Maxi-K+ channel beta1 expression in sleep apnea patients and its modulation by CPAP treatment. Am J Hypertens 2009; 22(2): 197-202.
5. Lin C, Yang Y. Changes of melatonin levels in patients with severe OSAHS after noninvasive ventilation. Contemporary Medicine 2018; 18: 11-13.
6. Kuzma-Kozakiewicz M. Edaravone in the treatment of amyotrophic lateral sclerosis. Neurol Neurochir Pol 2018; 52(2): 124-128.
7. Akaichi K, Namekata K, Azuchi Y, Guo X, Kimura A, Harada C, Mitamura Y, Harada T. Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma. Cell Death Dis 2017; 8(7): e2934.
8. Yu W, Chen FC, Xu WN, Ding SL, Chen PB, Yang L, Jiang SD, Pan XY. Inhibition of Y1 Receptor Promotes Osteogenesis in Bone Marrow Stromal Cells via cAMP/PKA/CREB Pathway. Front Endocrinol (Lausanne) 2020; 11: 583105.
9. Li XY, Qi WW, Zhang YX, Jiang SY, Yang B, Xiong L, Tong JC. Helicid Ameliorates Learning and Cognitive Ability and Activities cAMP/PKA/CREB Signaling in Chronic Unpredictable Mild Stress Rats. Biol Pharm Bull 2019; 42(7): 1146-1154.

10. World Health Organization. Principles of laboratory animal care. WHO Chron 1985; 39: 51-56.

11. Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988; 19(4): 480-485.

12. Nishi H, Watanabe T, Sakurai H, Yuki S, Ishibashi A. Effect of MCI-186 on brain edema in rats. Stroke 1989; 20(9): 1236-1240.

13. Alzoubi KH, Al Mosabih HS, Mahasneh AF. The protective effect of edaravone on memory impairment induced by chronic sleep deprivation. Psychiatry Res 2019; 281: 112577.

14. Lin C, Yang Y. Changes of melatonin levels in patients with severe OSAHS after noninvasive ventilation. Contemp Med 2018; 18: 44-46.

15. Lan C, Guanghui X, Yao T. Effect of home visit and telephone follow-up intervention on COPD-OSAHS patients treated with CPAP. Shanghai Nurs 2018; 18: 639-641.

16. Lee Y, Lee S, Park JW, Hwang JS, Kim SM, Lyoo IK, Lee CJ, Han IO. Hypoxia-Induced Neuroinflammation and Learning-Memory Impairments in Adult Zebrafish Are Suppressed by Glucosamine. Mol Neurobiol 2018; 55(11): 8738-8753.

17. Palorini R, De Rasmo D, Gaviraghi M, Sala Danna L, Signoni A, Cirulli C, Chiaradonna F, Alberghina L, Papa S. Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration. Oncogene 2013; 32(3): 352-362.

18. Bouchez C, Devin A. Mitochondrial Biogenesis and Mitochondrial Reactive Oxygen Species (ROS): A Complex Relationship Regulated by the cAMP/PKA Signaling Pathway. Cells 2019; 8(4): 280-287.

19. Zhao YN, Wang HY, Li JM, Chen BY, Xia G, Zhang PP, Ge YL. Hippocampal mitogen-activated protein kinase activation is associated with intermittent hypoxia in a rat model of obstructive sleep apnea syndrome. Mol Med Rep 2016; 13(1):137-145.

20. Ling J, Yu Q, Li Y, Yuan X, Wang X, Liu W, Guo T, Duan Y, Li L. Edaravone Improves Intermittent Hypoxia-Induced Cognitive Impairment and Hippocampal Damage in Rats. Biol Pharm Bull 2020; 43(8): 1196-1201.